Roche Diagnostics Gmbh

Hoffmann-La Roche Inc.

Roche Diagnostics Operations, Inc.

F. Hoffmann-La Roche Ag

Paul Lehmann

Ralf Roeddiger

Ruth Walter-Matsui

Ralf Roddiger

Lothar Thomas

Michael Harold Town

Horst Klima

Ren&eacute; Gottschalk

J&uuml;rgen Feuerstein

Joachim Peter Kaltwasser

Ralf Röddiger

The invention concerns a method for detecting disorders of iron metabolism and in particular the differential diagnosis of disorders of iron metabolism by means of three independent parameters. The differential diagnosis can be used to classify disorders of iron metabolism and to recommend the required treatment and to monitor the progress and response to treatment.

Diagnosis and treatment of disorders of iron metabolism

The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases.

Method of treating disturbances of iron distribution in inflammatory intestinal diseases

A method of, and pharmaceutical composition for, treating disturbances of iron distribution in diabetes using erythropoietin are disclosed.

Treatment of disturbances of iron distribution

The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in heart diseases.

The present invention concerns the use of hepcidin as a marker for detecting inflammatory chronic diseases and especially for a differential diagnosis to detect inflammatory chronic diseases and/or non-inflammatory chronic diseases. The present invention also concerns a method for detecting inflammatory chronic diseases, non-inflammatory chronic diseases and/or acute phase reactions comprising the determination of hepcidin.

Differential diagnosis with hepcidin

A pharmaceutical composition comprising 250-20,000 U of an EPO preparation and 5-20 mg of a Fe(III) complex is disclosed. This pharmaceutical composition is useful in treating anaemias as well or as haemodialysis patients.

Method for treating disturbances in iron metabolism using a combination of erythropoietin and iron

The combination of erythropoietin and calcium, with or without phosphates, is useful for treating haemochromatoses. A method for treating primary haemochromatoses in a patient involves administering to the patient a combination therapy including an erythropoietin preparation and a calcium preparation, where the erythropoietin preparation and the calcium preparation are each administered from 1 to 5 times weekly. Beneficially, this combination therapy further administers a phosphorus preparation.

Use of erythropoietin for the treatment of haemochromatoses

The present invention provides a pharmaceutical combination preparation comprising an erythropoietin preparation that provides active erythropoietin and at least one modified haemoglobin wherein the erythropoietin preparation and modified haemoglobin can be present in separate forms of administration or in a single form of administration. The pharmaceutical combination preparations of the present invention can be used to treat manifest anemias with or without iron utilization disorders.

Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins

The present invention is concerned with the use of individual administration forms of an erythropoietin preparation and a physiologically compatible iron preparation corresponding to an equivalent amount of 1-40 mg of iron ions for the production of a pharmaceutical combination preparation for the treatment of rheumatic diseases.

Growing community of inventors

Worms, Germany

Paul Lehmann